Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Human Mesenchymal Stromal Cells Clear all
Completed Phase 2 Interventional Results available

Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome

NCT03818854
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Human Mesenchymal Stromal Cells, Cell Reconstitution Media
Biological
Lead sponsor
Michael A. Matthay
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Sacramento, California • San Francisco, California • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure

NCT02467387
View directory record Official record
Conditions
Non-Ischemic Heart Failure
Interventions
Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Lactated Ringer's Solution
Drug
Lead sponsor
CardioCell LLC
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 1 Interventional

Tolerance by Engaging Antigen During Cellular Homeostasis

NCT03504241
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
Interventions
Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept, sirolimus, mycophenolate mofetil, mycophenolate acid, prednisone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

NCT04466098
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
Interventions
Mesenchymal stromal cells, Placebo
Biological · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Minneapolis, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 26, 2026, 10:38 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy

NCT04445220
View directory record Official record
Conditions
COVID-19, Acute Kidney Injury, Sepsis
Interventions
SBI-101
Biological
Lead sponsor
Sentien Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Results available

Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder

NCT04294290
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
hCT-MSC infusion
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Months to 48 Months
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 26, 2026, 10:38 AM EDT
No Longer Available No phase listed Expanded access

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection

NCT04366830
View directory record Official record
Conditions
Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19
Interventions
Remestemcel-L
Drug
Lead sponsor
Mesoblast International Sàrl
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 1 Interventional

Autologous Culture Expanded Mesenchymal Stromal Cells for Knee Osteoarthritis

NCT02805855
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Autologous Adipose-Derived Mesenchymal Stromal Cells
Drug
Lead sponsor
Jacob L. Sellon, M.D.
Other
Eligibility
40 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 1 Interventional

Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (DMD)

NCT02235844
View directory record Official record
Conditions
Duchenne's Muscular Dystrophy
Interventions
Umbilical Cord Mesenchymal Stem Cells
Biological
Lead sponsor
Allergy and Asthma Consultants, Wichita, Kansas
Other
Eligibility
28 Years to 31 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2019 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES)

NCT03818737
View directory record Official record
Conditions
Osteoarthritis
Interventions
Bone Marrow Derived MSCs, Adipose-derived MSCs, Umbilical Cord Tissue (UCT) MSCs, Corticosteroid injection
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
40 Years to 70 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Gulf Breeze, Florida • Atlanta, Georgia • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 1 Interventional

MSC for Occlusive Disease of the Kidney

NCT01840540
View directory record Official record
Conditions
Atherosclerotic Renal Artery Stenosis, Ischemic Nephropathy, Renovascular Hypertension
Interventions
Arterial infusion of autologous mesenchymal stem cells
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2017 · Synced Sep 26, 2026, 10:38 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis

NCT07339111
View directory record Official record
Conditions
Knee Cartilage Defects
Interventions
CARTISTEM® + Debridement, Debridement
Biological · Procedure
Lead sponsor
Medipost, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
30
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)

NCT02336230
View directory record Official record
Conditions
Grade B aGVHD, Grade C aGVHD, Grade D aGVHD
Interventions
remestemcel-L
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
2 Months to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
20
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Sep 26, 2026, 10:38 AM EDT
Withdrawn Phase 1 Interventional

Infusions of Mesenchymal Stromal Cells in Children With Multisystem Inflammatory Syndrome

NCT04549285
View directory record Official record
Conditions
Multisystem Inflammatory Syndrome in Children
Interventions
Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs)
Biological
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
18 Years to 20 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia • Westchester, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

hCT-MSC in Children With Autism Spectrum Disorder

NCT04089579
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Cord Tissue Mesenchymal Stromal Cells, Placebo Infusion
Biological · Other
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
4 Years to 11 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Early Phase 1 Interventional

Intra-Osseous Co-Transplant of UCB and hMSC

NCT02181478
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Myelofibrosis, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Lymphoid Malignancies, Chronic Myelogenous Leukemia
Interventions
cyclophosphamide, fludarabine phosphate, total-body irradiation, cyclosporine, mycophenolate mofetil, umbilical cord blood transplantation, mesenchymal stem cell transplantation
Drug · Radiation · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Sep 26, 2026, 10:38 AM EDT
Active, not recruiting Phase 1 Interventional

Autologous Culture Expanded Adipose Derived MSCs for Treatment of Painful Hip OA

NCT03608579
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Autologous Adipose Derived Mesenchymal Stromal Cells
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)

NCT02097641
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells, Plasma-Lyte A
Biological
Lead sponsor
Michael A. Matthay
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
San Francisco, California • Stanford, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 26, 2026, 10:38 AM EDT
Terminated Phase 1 Interventional

Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease

NCT04328714
View directory record Official record
Conditions
Acute Leukemia, Myelodysplastic Syndromes
Interventions
Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells
Drug
Lead sponsor
Edwin Horwitz
Other
Eligibility
1 Year and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 26, 2026, 10:38 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy

NCT03015623
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
SBI-101, Sham
Biological · Device
Lead sponsor
Sentien Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Sep 26, 2026, 10:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of UCB and MSCs in Children With CP: ACCeNT-CP

NCT03473301
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Infusion of allogeneic umbilical cord blood, Infusion of MSCs
Biological
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
24 Months to 60 Months
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Sep 26, 2026, 10:38 AM EDT
Active, not recruiting Phase 2 Interventional

Study of UC-MSC in DMD Patients

NCT06579352
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC)
Biological
Lead sponsor
MED Institute Inc.
Industry
Eligibility
5 Years to 10 Years · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Dallas, Texas • Flower Mound, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 26, 2026, 10:38 AM EDT
Withdrawn Phase 1 Interventional

Autologous Cell Therapy After Stroke

NCT00908856
View directory record Official record
Conditions
Stroke
Interventions
autologous bone marrow mononuclear cell transfusion, marrow stromal cells, placebo
Biological · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 26, 2026, 10:38 AM EDT
Terminated Phase 1 Interventional

Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma

NCT05035862
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Sulfate, Interferon gamma-primed mesenchymal stromal cells (MSCs), Prednisone
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 26, 2026, 10:38 AM EDT